-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Figure: Selective activation of the AMPK enzyme leads to leukemia cell death (purple in the figure)
Source: Jérôme Tamburini / UNIGE
Acute myeloid leukemia affects blood and bone marrow cells and is a particularly dangerous type of cancer
Associate Professor Jerome Tamburini at the Medical and Translational Research Centre Onco-Haematology UNIGE Faculty of Medicine (CRTOH) and Swiss Cancer Centre Chef (SCCL) and Professor at the University of Paris is studying the energy mechanisms of tumor cells in acute myeloid leukemia
In 2015, Jérôme Tamburini and his colleagues at Inserm in Paris were involved in the development of GSK621, a pharmacological ingredient in the GlaxoSmithKline (GSK) laboratory, which was shown to be an excellent activation of AMPK in vitro agent
Effective combination of two drugs
The first step, gene expression analysis of human tumor cells, identified an enzyme, PERK, that was particularly responsive to the presence of GSK621
The scientists then combined the two drugs in mice bearing human tumor cells and found that the combination was more effective at controlling tumor development than monotherapy
So what about leukemia stem cells?
Leukemia stem cells are present in a small group of cells within a tumor and can only be detected by their ability to spread the tumor again after the initial treatment has been successful
article title
AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia
